Healthcare stocks fade as obesity-drug optimism fades
By Dow Jones Newswires
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Viking Therapeutics shares (VKTX) gave back some of their recent gains amid skepticism about the biotech firm's attempt to compete with heavyweights such as Novo Nordisk on obesity drugs. Novo Nordisk (NVO) fell, shaving its gains for the year to date to around 25%.
Shares of Eiger BioPharmaceuticals (EIGR) plunged after the drug developer filed for chapter 11 bankruptcy with a deal in hand to sell its Zokinvy drug.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-01-24 2059ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks